Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
1.
Anal Sci ; 40(6): 1121-1128, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38592653

RESUMO

In this study, determination of (nitrogen containing) drugs by on-column complexation with metal ions in high-speed counter-current chromatography (HSCCC) was investigated. Bromazepam (BMP) was strongly retained in the organic upper stationary phase (UP) of the two-phase solvent system composed of tert-butyl methyl ether-acetonitrile-water (2:2:3, v/v/v) by eluting the aqueous lower mobile phase (LP) at a flow rate of 2 mL min-1. On the other hand, BMP (200 µg mL-1) was eluted faster without retention to the organic UP with the two-phase system containing 100 µg mL-1 of copper ions (CuCl2) because a very polar BMP-Cu2+ complex was immediately formed in the aqueous LP. The dramatic change in the retention behavior of BMP resulted from on-column complexation. The on-column complexation in HSCCC was further investigated for five (nitrogen containing) drugs and seven metal ions. In the result, tizanidine and phentolamine formed complexes with Al3+, Fe2+, Co2+, Ni2+, Cu2+, and Zn2+, ambroxol formed complexes with Al3+, Fe2+, and Cu2+, but voriconazole formed no complexes with all metal ions tested.


Assuntos
Distribuição Contracorrente , Metais , Metais/química , Preparações Farmacêuticas/química
2.
Case Rep Nephrol Dial ; 12(3): 163-166, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36518360

RESUMO

Benzodiazepine ingestion is frequent in patients admitted to ICU for intoxications. Generally, a supportive approach by securing the airway, breathing, and circulation is sufficient. Flumazenil is a well-known antidote for benzodiazepines but does not influence its elimination. Following preclinical data, we applied for the first time in humans a hemadsorption filter in a patient with a bromazepam intoxication. This technique proved to be effective in eliminating bromazepam in a patient with CHILD-C cirrhosis. We conclude that hemadsorption is a viable option to reduce length of ICU stay or intubation in slow metabolizers without contraindications.

3.
Pharmacol Rep ; 74(5): 956-968, 2022 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-36097257

RESUMO

BACKGROUND: Anxiolytic benzodiazepines, due to their clinical effectiveness, are one of the most prescribed drugs worldwide, despite being associated with sedative effects and impaired psychomotor and cognitive performance. Not every GABAA receptor functions in the same manner. Those containing α1 subunits are associated with sleep regulation and have a greater effect on the sedative-hypnotic benzodiazepines, whereas those containing α2 and/or α3 subunits are associated with anxiety phenomena and have a greater effect on the anxiolytic benzodiazepines. Therefore, characterization of the selectivity profile of anxiolytic drugs could translate into a significant clinical impact. METHODS: The present study pharmacodynamically evaluated chlornordiazepam, the main active metabolite of mexazolam, upon GABAA receptors containing α2 and/or α3, anxiety-related, and those containing an α1 subunit, associated with sleep modulation. RESULTS: As shown by whole-cell patch-clamp data, chlornordiazepam potentiated GABA-evoked current amplitude in α2 and α3 containing receptors without changing the current amplitude in α1 containing receptors. However, current decay time increased, particularly in GABAA receptors containing α1 subunits. In contrast, other anxiolytic benzodiazepines such as alprazolam, bromazepam, and zolpidem, all increased currents associated with GABAA receptors containing the α1 subunit. CONCLUSIONS: This novel evidence demonstrates that mexazolam (through its main metabolite chlornordiazepam) has a "pharmacodynamic fingerprint" that correlates better with an anxiolytic profile and fewer sedative effects, when compared to alprazolam, bromazepam and zolpidem, explaining clinical trial outcomes with these drugs. This also highlights the relevance of the pharmacological selectivity over GABAA receptor subtypes in the selection of benzodiazepines, in addition to their clinical performance and pharmacokinetic characteristics.


Assuntos
Ansiolíticos , Bromazepam , Receptores de GABA-A/metabolismo , Zolpidem , Alprazolam/farmacologia , Ansiolíticos/farmacologia , Bromazepam/farmacologia , Benzodiazepinas/farmacologia , Hipnóticos e Sedativos/farmacologia , Ácido gama-Aminobutírico
4.
J Inorg Biochem ; 237: 112012, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36162209

RESUMO

A significant fraction of patients are affected by persistent fear and anxiety. Currently, there are several anxiolytic drug options, however their clinical outcomes do not fully manage the symptoms. Here, we evaluated the effects of a bromazepam­palladium derivative [2-{(7-bromo-2-oxo-1,3-dihydro-2H-1,4-benzodiazepin-5-il)pyridinyl-κ2-N,N}chloropalladium(II)], [(BMZ)PdCl2], on fear/anxiety and memory-related behavior in mice. For this, female Swiss mice were treated intraperitoneally (i.p.) with saline (NaCl 0.9%) or [(BMZ)PdCl2] (0.5, 5.0, or 50 µg/kg). After 30 min, different tests were performed to evaluate anxiety, locomotion, and memory. We also evaluated the acute toxicity of [(BMZ)PdCl2] using a cell viability assay (neutral red uptake assay), and whether the drugs mechanism of action involves the γ-aminobutyric acid type A (GABAA) receptor complex by pre-treating animals with flumazenil (1.0 mg/kg, i.p., a competitive antagonist of GABAA-binding site). Our results demonstrate that [(BMZ)PdCl2] induces an anxiolytic-like phenotype in the elevated plus-maze test and that this effect can be blocked by flumazenil. Furthermore, there were no behavioral alterations induced by [(BMZ)PdCl2], as evaluated in the light-dark box, open field, and step-down passive avoidance tests. In the acute toxicity assay, [(BMZ)PdCl2] presented IC50 and LD50 values of 218 ± 60 µg/mL and 780 ± 80 mg/kg, respectively, and GSH category 4. Taken together, our results show that the anxiolytic-like effect of acute treatment with [(BMZ)PdCl2] occurs through the modulation of the benzodiazepine site in the GABAA receptor complex. Moreover, we show indications that [(BMZ)PdCl2] does not promote sedation and amnesia and presents the same toxicity as the bromazepam prototype.


Assuntos
Ansiolíticos , Bromazepam , Animais , Camundongos , Feminino , Ansiolíticos/farmacologia , Ansiolíticos/uso terapêutico , Flumazenil/farmacologia , Bromazepam/farmacologia , Paládio/farmacologia , Ácido gama-Aminobutírico , Comportamento Animal , Aprendizagem em Labirinto
5.
Conscious Cogn ; 100: 103317, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-35364385

RESUMO

AIM: This study investigated the bromazepam effects in male subjects during the time estimation performance and EEG alpha asymmetry in electrodes associated with the frontal and motor cortex. MATERIAL AND METHODS: This is a double-blind, crossover study with a sample of 32 healthy adults under control (placebo) vs. experimental (bromazepam) during visual time-estimation task in combination with electroencephalographic analysis. RESULTS: The results demonstrated that the bromazepam increased the relative error in the 4 s, 7 s, and 9 s intervals (p = 0.001). In addition, oral bromazepam modulated the EEG alpha asymmetry in cortical areas during the time judgment (p ≤ 0.025). CONCLUSION: The bromazepam decreases the precision of time estimation judgments and modulates the EEG alpha asymmetry, with greater left hemispheric dominance during time perception. Our findings suggest that bromazepam influences internal clock synchronization via the modulation of GABAergic receptors, strongly relating to attention, conscious perception, and behavioral performance.


Assuntos
Bromazepam , Percepção do Tempo , Adulto , Bromazepam/farmacologia , Estudos Cross-Over , Método Duplo-Cego , Eletroencefalografia/métodos , Humanos , Julgamento , Masculino
6.
Rev. Ciênc. Méd. Biol. (Impr.) ; 20(4): 526-532, fev 11, 2022. tab
Artigo em Português | LILACS | ID: biblio-1359308

RESUMO

Introdução: embora o câncer seja um dos maiores problemas de saúde pública enfrentados mundialmente, diversas substâncias presentes no meio, como os fármacos, não estão muito bem elucidadas sobre seu possível potencial carcinogênico. Entre eles, estão os benzodiazepínicos, fármacos que possuem crescente aumento do consumo desde o século XX e, principalmente, na segunda década do século XXI, por suas ações ansiolíticas, sedativas e anticonvulsivantes. Objetivo: avaliar o efeito carcinogênico do bromazepam por meio do teste para detecção de tumores epiteliais (ETT) em Drosophila melanogaster. Metodologia: para realização do ETT foram utilizadas duas linhagens mutantes de D. melanogaster: wts (fêmeas) e mwh (machos). As larvas descendentes desse cruzamento foram tratadas isoladamente com cinco concentrações de bromazepam, sendo elas: 0,0375; 0,075; 0,15; 0,30 e 0,60 mM. A Doxorrubicina foi utilizada como controle positivo e a água ultrapura como controle negativo. Após tratamento, coleta e armazenamento, as moscas foram analisadas, identificando-se as frequências tumorais, por região corporal, em cada concentração testada. Resultados: o bromazepam não apresentou efeito carcinogênico em nenhuma das concentrações experimentadas neste estudo, não havendo diferença estatisticamente significativa nas frequências tumorais observadas nos indivíduos tratados com bromazepam quando comparadas à frequência obtida nos indivíduos tratados com o controle negativo. Conclusão: Nas presentes condições experimentais, o bromazepam não apresentou atividade carcinogênica, no entanto, há a necessidade de novos estudos, com diferentes metodologias e diferentes organismos testes, para a maior compreensão da ação do bromazepam no organismo.


Introduction: although cancer is one of the biggest public health problems faced worldwide, several substances present in the environment, such as drugs are not very well understood about its possible carcinogenic potential. Among them are benzodiazepines, drugs that have increased their consumption since the 20th century and, mainly, in the second decade of the 21st century, due to their anxiolytic, sedative and anticonvulsant actions. Objective: Evaluate the carcinogenic effect of bromazepam through the test to detect epithelial tumor clones (ETT) in Drosophila melanogaster. Methodology: to perform the ETT, two mutant strains of D. melanogaster were used: wts (female) and mwh (male). The descending larves of this cross were treated separately with five concentrations of bromazepam, namely: 0.0375; 0.075; 0.15; 0.30 and 0.60 mM. Doxorubicin was used as a positive control and ultrapure water as a negative control. After treatment, collection and storage, the flies were analyzed, identifying the tumor frequencies, by body region, at each concentration tested. Results: bromazepam did not have a carcinogenic effect at any of the concentrations experienced in this study, with no statistically significant difference in tumor frequencies observed in individuals treated with bromazepam when compared to the frequency obtained in individuals treated with the negative control. Conclusion: In the present experimental conditions, bromazepam did not show carcinogenic activity, however, there is a need for further studies with different methodologies and different test organisms to better understand the action of bromazepam in the body.


Assuntos
Animais , Masculino , Feminino , Bromazepam , Carcinoma , Drosophila melanogaster , Carcinogênese , Larva , Epitélio
8.
Spectrochim Acta A Mol Biomol Spectrosc ; 238: 118433, 2020 Sep 05.
Artigo em Inglês | MEDLINE | ID: mdl-32403074

RESUMO

Four simple, sensitive and selective stability indicating spectrophotometric methods are presented for quantitative determination of the benzodiazepine drug; bromazepam (BMZ) and one of its reported potential impurities and degradation product; 2-(2-amino-5-bromobenzoyl) pyridine (ABP) in methanol. Method A, is isoabsorptive point coupled with D0 method, where good linearity was obtained by measuring the absorbance of BMZ at 264 nm (Aiso) in the concentration range of 2-25 µg mL-1, and the absorbance of ABP at its λmax 396 nm in concentration range of 0.5-24 µg mL-1. Method B, is ratio subtraction; the absorbance was measured at 233 nm for BMZ using 20 µg mL-1 of ABP, while ABP was determined directly at its λmax 396 nm using methanol as a solvent. Method C, was based on measuring the total peak amplitude of the first derivative of the ratio spectra (DD1) of BMZ from 301 to 326 nm using 10 µg mL-1 of ABP as a divisor and determination of ABP at peak amplitude of 293 nm using 5 µg mL-1 of BMZ as a divisor. In method D, ratio difference method, good linearity was achieved for determination of BMZ and ABP by measuring the differences between the amplitudes of ratio spectra at 312 nm and 274 nm and differences between the amplitudes of ratio spectra at 274 nm and 312 nm, respectively. The stability of BMZ was investigated under different ICH recommended forced degradation conditions. The suggested methods were then successfully applied for determination of BMZ in its pharmaceutical formulations.


Assuntos
Ansiolíticos/análise , Bromazepam/análise , Contaminação de Medicamentos , Estabilidade de Medicamentos , Oxirredução , Espectrofotometria/métodos
9.
Pharmacol Res ; 145: 104250, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31059790

RESUMO

Etifoxine (EFX) is a non-benzodiazepine psychoactive drug which exhibits anxiolytic effects through a dual mechanism, by directly binding to GABAA receptors (GABAARs) and to the mitochondrial 18-kDa translocator protein, resulting in the potentiation of the GABAergic function. The ß subunit subtype plays a key role in the EFX-GABAAR interaction, however this does not explain the anxiolytic effects of this drug. Here, we combined behavioral and electrophysiological experiments to challenge the role of the GABAAR α subunit in the EFX mode of action. After single administrations of anxiolytic doses (25-50 mg/kg, intraperitoneal), EFX did not induce any neurological nor locomotor impairments, unlike the benzodiazepine bromazepam (0.5-1 mg/kg, intraperitoneal). We established the EFX pharmacological profile on heteropentameric GABAARs constructed with α1 to α6 subunit expressed in Xenopus oocyte. Unlike what is known for benzodiazepines, neither the γ nor δ subunits influenced EFX-mediated potentiation of GABA-evoked currents. EFX acted first as a partial agonist on α2ß3γ2S, α3ß3γ2S, α6ß3γ2S and α6ß3δ GABAARs, but not on α1ß3γ2S, α4ß3γ2S, α4ß3δ nor α5ß3γ2S GABAARs. Moreover, EFX exhibited much higher positive allosteric modulation towards α2ß3γ2S, α3ß3γ2S and α6ß3γ2S than for α1ß3γ2S, α4ß3γ2S and α5ß3γ2S GABAARs. At 20 µM, corresponding to brain concentration at anxiolytic doses, EFX increased GABA potency to the highest extent for α3ß3γ2S GABAARs. We built a docking model of EFX on α3ß3γ2S GABAARs, which is consistent with a binding site located between α and ß subunits in the extracellular domain. In conclusion, EFX preferentially potentiates α2ß3γ2S and α3ß3γ2S GABAARs, which might support its advantageous anxiolytic/sedative balance.


Assuntos
Ansiolíticos/farmacologia , Oxazinas/farmacologia , Subunidades Proteicas/metabolismo , Receptores de GABA-A/metabolismo , Animais , Ansiolíticos/uso terapêutico , Ansiedade/tratamento farmacológico , Ansiedade/metabolismo , Ansiedade/fisiopatologia , Feminino , Locomoção/efeitos dos fármacos , Masculino , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Modelos Moleculares , Oócitos/fisiologia , Oxazinas/uso terapêutico , Subunidades Proteicas/genética , Desempenho Psicomotor/efeitos dos fármacos , Receptores de GABA-A/genética , Xenopus laevis
10.
Pharmacology ; 104(1-2): 1-6, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30943497

RESUMO

AIM: To assess the effects of chronic evening oral administration of bromazepam alone or in combination with propranolol on ambulatory blood pressure (BP) and heart rate (HR) in mild hypertensive subjects. METHODS: Thirty-seven mild hypertensive patients after a 2-week placebo period were randomized to bromazepam 3 mg, propranolol 40 mg, bromazepam 3 mg plus propranolol 40 mg or placebo for 2 weeks according to a double-blind, double dummy, cross-over design. After each treatment period, 24-h BP and HR ambulatory monitoring was performed by using a non-invasive device. RESULTS: Ambulatory monitoring showed that during night-time SBP and DBP values were unaffected by bromazepam as compared to placebo, whereas SBP was significantly reduced by propranolol both when taken alone and in combination with bromazepam. HR nocturnal values were significantly reduced by propranolol, whereas they were significantly increased by bromazepan both when taken alone (+11.5%, p < 0.05 vs. placebo) and in combination with propranolol (+12.8%, p < 0.05 vs. propranolol). No significant difference in day-time values of SBP, DBP and HR was observed among the 4 treatment groups. CONCLUSIONS: In mild hypertensive patients, evening consumption of bromazepam for a 2-week period did not affect BP, while it increased nocturnal HR. Such an increase was observed both when bromazepam was taken alone and in combination with propranolol, which suggests that it depends on a bromazepam mediated decrease in vagal tone. Whatever the mechanism, the HR nocturnal increase might be of clinical relevance, due to the role of high HR as cardiovascular risk factor, particularly in already at risk hypertensive subjects.


Assuntos
Pressão Sanguínea/efeitos dos fármacos , Bromazepam/administração & dosagem , Frequência Cardíaca/efeitos dos fármacos , Hipertensão/tratamento farmacológico , Propranolol/administração & dosagem , Administração Oral , Pressão Sanguínea/fisiologia , Monitorização Ambulatorial da Pressão Arterial , Ritmo Circadiano/fisiologia , Estudos Cross-Over , Método Duplo-Cego , Esquema de Medicação , Quimioterapia Combinada/métodos , Feminino , Frequência Cardíaca/fisiologia , Humanos , Hipertensão/diagnóstico , Hipertensão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Resultado do Tratamento
11.
Chemosphere ; 176: 324-332, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28273540

RESUMO

Pharmaceuticals as environmental contaminants have received a lot of interest over the past decade but, for several pharmaceuticals, relatively little is known about their occurrence in European surface waters. Benzodiazepines, a class of pharmaceuticals with anxiolytic properties, have received interest due to their behavioral modifying effect on exposed biota. In this study, our results show the presence of one or more benzodiazepine(s) in 86% of the analyzed surface water samples (n = 138) from 30 rivers, representing seven larger European catchments. Of the 13 benzodiazepines included in the study, we detected 9, which together showed median and mean concentrations (of the results above limit of quantification) of 5.4 and 9.6 ng L-1, respectively. Four benzodiazepines (oxazepam, temazepam, clobazam, and bromazepam) were the most commonly detected. In particular, oxazepam had the highest frequency of detection (85%) and a maximum concentration of 61 ng L-1. Temazepam and clobazam were found in 26% (maximum concentration of 39 ng L-1) and 14% (maximum concentration of 11 ng L-1) of the samples analyzed, respectively. Finally, bromazepam was found only in Germany and in 16 out of total 138 samples (12%), with a maximum concentration of 320 ng L-1. This study clearly shows that benzodiazepines are common micro-contaminants of the largest European river systems at ng L-1 levels. Although these concentrations are more than a magnitude lower than those reported to have effective effects on exposed biota, environmental effects cannot be excluded considering the possibility of additive and sub-lethal effects.


Assuntos
Benzodiazepinas/análise , Monitoramento Ambiental/métodos , Rios/química , Poluentes Químicos da Água/análise , Clobazam , Europa (Continente) , Oxazepam/análise , Temazepam/análise
12.
Curr Drug Saf ; 12(1): 57-61, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28067180

RESUMO

BACKGROUND: Dispensing patterns reflect drug usage trends. Benzodiazepines are known as drugs with potential for misuse, and frequent dispensing may be a surrogate marker of misuse. OBJECTIVE: The primary aim of this study was to obtain a comparative snapshot of anxiolytic and sedative-hypnotic dispensing in a developing country and a developed country, to determine whether further research about benzodiazepines is warranted. METHOD: A cross-national, cross-sectional retrospective drug utilisation study was conducted on benzodiazepines and z-drugs. The South African database was obtained from a national medical insurance administrator and the Australian data were de-identified and extracted from pharmacies in the city of Brisbane in Queensland. RESULTS: Diazepam was the most frequently dispensed anxiolytic in the Australian dataset (26.4%; n=1057/4010) while in the South African data, diazepam dispensing (17.2%; n=11597/67354) was superseded by alprazolam (17.8%; n=12009/67354) and followed by bromazepam (13.6%; n=9146/67354). The most frequently dispensed hypnotic in the South African data was zolpidem which accounted for 18.7% of records (n=12603/67354), while in the Australian data it was temazepam (24.9%; n=998/4010). Zolpidem was dispensed more frequently than zopiclone in both datasets. CONCLUSION: In South Africa there was relatively frequent use of alprazolam, bromazepam and zolpidem while in the Australian data diazepam, oxazepam and temazepam were most frequently dispensed. The use of alprazolam, identified as a drug of abuse in Australia, warrants further research in South Africa. The indicator described in this paper permitted a (qualitative) cross-sectional comparison of anxiolytics and sedative-hypnotics between a developed and a developing country (Australia and South Africa).


Assuntos
Ansiolíticos/uso terapêutico , Bases de Dados Factuais/tendências , Países em Desenvolvimento , Prescrições de Medicamentos , Uso de Medicamentos/tendências , Hipnóticos e Sedativos/uso terapêutico , Austrália/epidemiologia , Estudos Transversais , Estudos de Viabilidade , Humanos , Estudos Retrospectivos , África do Sul/epidemiologia
13.
São Paulo; s.n; abr. 2016. 58 p
Tese em Português | Index Psicologia - Teses | ID: pte-68874

RESUMO

Benzodiazepínicos são as drogas lícitas mais vendidas no Brasil - certa de 50 milhões de brasileiros fazem uso diário desse tipo de droga. É clara a importância de se conhecer os efeitos que essas drogas podem ter sobre o comportamento. Existem diversas lacunas no conhecimento de como afetam diferentes aspectos do comportamento operante, entretanto. Especificamente, o efeito do tratamento sobre o responder por reforçadores condicionados tem sido uma área pouco explorada. O presente estudo se propôs a investigar os efeitos do tratamento com bromazepam sobre o responder por um estímulo condicionado e um incondicionado, em dois esquemas complementares, razão progressiva e segunda ordem. Foram conduzidos três experimentos. Experimento I: 9 ratas de aproximadamente 9 meses de idade foram submetidas à um esquema de razão progressiva, tendo um composto de luz (LUZ) e solução de sacarose (SAC) como consequência; uma vez obtida uma linha de base foi iniciado tratamento com 1 mg/kg de bromazepam em 4 dos sujeitos (BRO) e salina (VEI) nos demais. Após 28 dias, foi removida SAC. Após 8 dias, foi removida também LUZ. Ocorreram então 5 sessões de extinção. Foi observada uma redução no responder durante o tratamento em BRO. O tratamento não apresentou efeitos adicionais durante a fase de remoção das consequências. Experimento II: replicação do I utilizando 18 machos de aproximadamente 3 meses de idade e com uma entrefase de adaptação ao procedimento de injeção. O tratamento levou ao aumento do responder em BRO (F2,23=8,13; p=0,001), porém não trouxe diferenças após a remoção das consequências. Experimento III: 20 ratos machos de 3 meses de idade foram submetidos à duas fases experimentais: manutenção (no qual, por quatro dias, eram expostos à esquemas de segunda ordem de Razão/Intervalo com a duração do intervalo crescente a cada sessão (FI 2min (FR5:luz); FI 5min(FR5:luz); FI10min(FR5:luz) e FI20min(FR5:luz), e teste (T1 FI20min(FR5luz)), T2 FR5 e T3 FI20min)... (AU)


Benzodiazepines are the most sold of legal drugs in Brazil about 50 million Brazilians use this kind of drug on a daily basis. The importance of knowing the effects of these drugs on behavior is clear. There are several gaps in the knowledge of these drugs affect operant behavior, however. Specifically, the effect of treatment on the responding for conditioned reinforcements is an area that has seldom been investigated. The present study proposed to investigate the effects of bromazepam treatment on the responding for a conditioned and an unconditioned stimulus, in two complementary schedules, namely, progressive ratio and second order. Three experiments were held. Experiment I: 9 female rats of approximately 9 months of age underwent a progressive ratio schedule, with a sucrose solution (SUC) and a light presentation (LIGHT) as concomitant consequences. Once baseline was stablished, treatment with 1mg/kg bromazepam was started for 4 subjects (BRO). The remaining received saline (VEI). After 29 days, SAC was removed. After 8 days, LIGHT was also removed. Then 5 sessions of extinction took place. Lower responding was observed in BRO. Treatment did not further effect behavior in the remaining experimental stages (consequence removal). Experiment II: pilot replication using 18 male rats and including a stage of habituation to the injection procedure. Treatment incurred in the increase of responding for BRO (F2,23=8.13; p=0.001), but had no further effects on the subsequent stages. Experiment III: 20 male rats underwent two experimental stages: maintenance (for four days the animal underwent second order schedules composed of a Ratio and an Interval component, in which the interval increased with each session ( (FI 2min(FR5:light); FI 5min(FR5light); FI10min(FR5light) E FI20min(FR5light) and test (T1 FI20min(FR5light)), T2 FR5 and T3 FI20min). Maintenance stages were intended to stablish and strengthen the LIGHT/SUC relation. VEI responded in a ... (AU)

14.
Arq. neuropsiquiatr ; 73(4): 321-329, 04/2015. graf
Artigo em Inglês | LILACS | ID: lil-745753

RESUMO

The present study investigates the influence of bromazepam while executing a motor task. Specifically, we intend to analyze the changes in alpha absolute power under two experimental conditions, bromazepam and placebo. We also included analyses of theta and beta frequencies. We collected electroencephalographic data before, during, and after motor task execution. We used a Two Way ANOVA to investigate the condition (PL × Br6 mg) and moment (pre and post) variables for the following electrodes: Fp1, Fp2, F7, F3, Fz, F4, F8, C3, CZ and C4. We found a main effect for condition on the electrodes FP1, F7, F3, Fz, F4, C3 and CZ, for alpha and beta bands. For beta band we also found a main effect for condition on the electrodes Fp2, F8 and C4; for theta band we identified a main effect for condition on C3, Cz and C4 electrodes. This finding suggests that the motor task did not have any influence on the electrocortical activity in alpha, and that the existing modifications were a consequence due merely to the drug use. Despite its anxiolytic and sedative action, bromazepam did not show any significant changes when the individuals executed a finger extension motor task.


O presente estudo investiga a influência do bromazepam durante a execução de uma tarefa motora. Especificamente, pretende-se analisar as mudanças na potência absoluta de alfa sob duas condições experimentais, bromazepam e placebo. Nós também incluímos as analises das frequências teta e beta. Foram coletados dados eletroencefalográficos antes, durante e depois da execução da tarefa motora. Usamos uma Anova de 2 fatores para investigar a condição (PL × Br6 mg) e variáveis no momento (pré e pós) para os seguintes eletrodos: Fp1, Fp2, F7, F3, Fz, F4, F8, C3, C4 e CZ. Encontramos um efeito principal para a condição e eletrodos FP1, F7, F3, Fz, F4, C3 e CZ para alfa e beta. Para beta também foi encontrado um efeito principal para condição nos eletrodos Fp2, F8 e C4; para theta nós identificamos um efeito principal para condition em C3, Cz e C4. Este achado sugere que a tarefa motora não tem qualquer influência sobre a atividade eletrocortical alfa e que as modificações existentes foram uma consequência devido o uso de drogas. Apesar de sua ação ansiolítica e sedativa, o bromazepam não apresentou mudança significativa quando os indivíduos executaram uma tarefa motora.


Assuntos
Adulto , Feminino , Humanos , Masculino , Adulto Jovem , Ansiolíticos/farmacologia , Bromazepam/farmacologia , Lobo Frontal/efeitos dos fármacos , Destreza Motora/efeitos dos fármacos , Córtex Somatossensorial/efeitos dos fármacos , Análise de Variância , Ondas Encefálicas/efeitos dos fármacos , Método Duplo-Cego , Eletroencefalografia/efeitos dos fármacos , Lobo Frontal/fisiologia , Atividade Motora/efeitos dos fármacos , Valores de Referência , Córtex Somatossensorial/fisiologia , Análise e Desempenho de Tarefas , Fatores de Tempo
15.
Clin EEG Neurosci ; 46(4): 292-8, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25394638

RESUMO

Bromazepam is a benzodiazepine, which has been widely employed in the treatment of anxiety. We investigated the electrophysiological changes in absolute theta power within the frontal cortex when individuals performed a visuomotor task under bromazepam. The sample of 17 healthy individuals was randomized into 2 experimental conditions, under which bromazepam 6 mg and placebo were administered on different days. All subjects were right -handed, with no mental or physical illness and were not using any psychoactive or psychotropic substance during the entire period of the study. We found an increase in reaction time under bromazepam compared with placebo . With regard to the electrophysiological variable, we found a lower theta power value in the prefrontal cortex prior to task execution, compared with after. We therefore suggested that this could be an increase of neural activity in this region, because of the subjects' readiness to perform the task, that is, because of their higher alertness. The right lateral frontal region showed lower theta power under bromazepam for pre- and post-finger movement. This could have occurred because of more effort to execute the task. In the left frontal region: premovement did not demonstrate any difference between conditions, possibly because the proposed task was simple to execute. In conclusion, theta power plays an important role in the analysis of visuomotor performance, assuming that bromazepam causes impairment on sustained attention and sensory perception.


Assuntos
Ansiolíticos/farmacologia , Atenção/efeitos dos fármacos , Bromazepam/farmacologia , Eletroencefalografia , Lobo Frontal/efeitos dos fármacos , Desempenho Psicomotor/efeitos dos fármacos , Ritmo Teta/efeitos dos fármacos , Acelerometria , Adolescente , Adulto , Método Duplo-Cego , Feminino , Voluntários Saudáveis , Humanos , Masculino , Testes Neuropsicológicos , Estimulação Luminosa
16.
Dermatol Ther ; 27(6): 361-4, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25052839

RESUMO

Vibratory angioedema is a rare form of physical urticaria, hereditary or acquired, which occurs at body sites exposed to vibrations. Pathogenic mechanisms of disease are not completely clear and, consequently, current pharmacological treatment is sometimes unsatisfactory. We report the case of a horn player affected by acquired vibratory angioedema, relapsing after prolonged use of the instrument and resistant to systemic antihistamines and corticosteroids, which successfully responded to therapy with low doses of amitriptyline and bromazepam. A neuroinflammatory mechanism can be likely implicated in the pathogenesis of vibratory angioedema, in line with many different cutaneous/mucosal diseases involving a complex interplay of homeostatic/allostatic systems. Furthermore, in mucosal diseases, such as vibratory angioedema, physical/psychological stressors have a relevant role. In such cases, because of the complex interplay between nervous and immune system, the pharmacological activity of benzodiazepines and typical antidepressants may downregulate neuroinflammation.


Assuntos
Amitriptilina/uso terapêutico , Angioedema/tratamento farmacológico , Anti-Inflamatórios/uso terapêutico , Bromazepam/uso terapêutico , Hipersensibilidade Imediata/congênito , Música , Angioedema/diagnóstico , Angioedema/etiologia , Antidepressivos/uso terapêutico , Quimioterapia Combinada , Humanos , Hipersensibilidade Imediata/diagnóstico , Hipersensibilidade Imediata/tratamento farmacológico , Hipersensibilidade Imediata/etiologia , Masculino , Resultado do Tratamento , Vibração/efeitos adversos , Adulto Jovem
17.
J Pharm Anal ; 2(6): 484-491, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29403788

RESUMO

The purpose of this work was to develop a rapid, sensitive and validated HPLC method for the separation and analysis of a Bromazepam, Medazepam and Midazolam mixture. The three benzodiazepine compounds were separated on a reversed-phase C18 column at 50 °C using a mobile phase containing 25% acetonitrile, 45% methanol and 30% ammonium acetate (0.05 M). The pH was adjusted to pH=9 by the addition of ammonia solution (35%, w/w). The samples were detected using a UV detector at 240 nm. The validation study of the method included the effect of temperature, flow rate, ratio of the components of the mobile phase and the pH of the mobile phase on the efficiency of separation. The linear range of Bromazepam and Midazolam was between 0.12 and 0.18 mg/mL, while that of Medazepam was between 0.08 and 0.12 mg/mL. The relative standard deviation for precision was less than 2%. The linearity, selectivity, accuracy and robustness of the developed method showed acceptable values. The method was applied to the analysis of the samples of raw material of the three compounds under study, and the percentage of recoveries was 99.89%±1.06. It was also applied to the analysis of samples of pharmaceutical preparations of those compounds and spiked serum samples. Recoveries from serum samples ranged between 91.5% and 99.0%. The developed method is suitable for quality control of Bromazepam, Medazepam and Midazolam in their mixtures and in pharmaceutical preparations (tablets, capsules, ampoules). It can also be used to determine their concentrations in serum.

18.
Arq. neuropsiquiatr ; 67(2a): 214-218, June 2009. graf
Artigo em Inglês | LILACS | ID: lil-517030

RESUMO

This study aimed to elucidate cortical mechanisms and to identify the areas where occur such mechanisms due to interaction between bromazepam and motor learning. The sample was composed of 45 healthy subjects randomly distributed in 3 groups: placebo (n=15), bromazepam 3 mg (n=15) or bromazepam 6 mg (n=15). To perform the experimental task, subjects sat comfortably at a distance of approximately 20 cm from the typewriter. The typewriter keyboard was covered with a wooden box to avoid visual information about the hands' position. The typewriting task was performed concomitantly with EEG recording. ANOVA two-way results indicated a decreased asymmetry in sensorimotor areas in the experimental groups. Our interpretation is that moderate doses of bromazepam may improve performance on tasks with predictable elements to promote stability of psychomotor functions, but may also impair performance on tasks executed in unpredictable environments.


O objetivo do estudo foi elucidar mecanismos corticais e identificar as áreas onde estas ocorrem tais mecanismos devido à interação entre bromazepam e aprendizagem motora. A amostra compreendeu 45 sujeitos hígidos distribuídos randomicamente em 3 grupos: placebo (n=15), bromazepam 3 mg (n=15) ou bromazepam 6 mg (n=15). Para a realização da tarefa experimental, sujeitos sentaram-se confortavelmente a uma distância de aproximadamente 20 cm da máquina de escrever. O teclado da máquina foi coberto com uma caixa de madeira para evitar informações visuais sobre a posição das mãos. O registro do EEGq ocorreu simultaneamente à tarefa de datilografia. Os resultados da ANOVA two-way indicaram menor assimetria em áreas sensório-motoras nos grupos experimentais. Nossa interpretação é que doses moderadas de bromazepam podem melhorar o desempenho em tarefas previsíveis por promover estabilidade das funções psicomotoras, mas pode prejudicar o desempenho em tarefas realizadas em ambientes imprevisíveis.


Assuntos
Adulto , Feminino , Humanos , Masculino , Adulto Jovem , Bromazepam/farmacologia , Eletroencefalografia/efeitos dos fármacos , Lateralidade Funcional/efeitos dos fármacos , Moduladores GABAérgicos/farmacologia , Aprendizagem/efeitos dos fármacos , Desempenho Psicomotor/efeitos dos fármacos , Análise de Variância , Bromazepam/administração & dosagem , Método Duplo-Cego , Lateralidade Funcional/fisiologia , Moduladores GABAérgicos/administração & dosagem , Aprendizagem/fisiologia , Testes Neuropsicológicos , Desempenho Psicomotor/fisiologia , Adulto Jovem
19.
An. acad. bras. ciênc ; 80(2): 335-340, June 2008. ilus, graf
Artigo em Inglês | LILACS | ID: lil-482888

RESUMO

The EEG has been widely employed in the assessment of electrophysiological changes induced by distinct medications. Its sensibility in detecting alterations produced by a specific substance may be enhanced by methods of quantitative analyses (qEEG). The present study aimed at investigating the modulatory effects of bromazepam on brain dynamics. The effects of bromazepam (3mg) on EEG power distribution were tested in 10 healthy individuals, in a double-blind experiment. The electrophysiological measure was analyzed across experimental conditions, moments, and electrodes, in the delta, theta, alpha and beta frequency bands separately. A significant decrease of relative power was observed in delta and theta (main effect of condition). No interactions were observed. Although the expected anxiolytic EEG profile was not observed (increased beta and decreased alpha activity), this specific result may be related to other factors such as dosage used and the subjects' general physiological state, and not necessarily to the drug itself.


O EEG tem sido amplamente empregado na avaliação de mudanças eletrofisiológicas induzidas por medicações distintas.A sensibilidade desta técnica em detectar alterações produzidas por uma substância pode ser aprimorada por métodos de análise quantitativa (EEGq). O presente estudo teve por objetivo investigar os efeitos modulatórios do bromazepam na dinâmica cerebral. Os efeitos de 3mg de bromazepam na distribuição de potência cortical foram observados em 10 indivíduos sadios, em um desenho duplo-cego. A medida eletrofisiológica foi analisada nas diferentes condições experimentais, momentos e eletrodos, em delta, teta, alfa e beta separadamente. Uma diminuição significativa de potência relativa foi observada em delta e teta (efeito principal para condição). Não foram observadas interações. Embora o perfil ansiolítico do EEG (aumento de beta e diminuição de alfa) não tenha sido observado, esteresultado específico pode estar relacionado a outros fatores, tais como dose utilizada e estado fisiológico dos sujeitos, e não necessariamente à droga propriamente dita.


Assuntos
Adulto , Feminino , Humanos , Masculino , Ansiolíticos/farmacologia , Bromazepam/farmacologia , Eletroencefalografia/efeitos dos fármacos , Córtex Motor/efeitos dos fármacos , Análise de Variância , Método Duplo-Cego , Córtex Motor/fisiologia
20.
Arq. neuropsiquiatr ; 65(4a): 955-959, dez. 2007. graf
Artigo em Inglês | LILACS | ID: lil-470121

RESUMO

The early stages of visual information processing, involving the detection and perception of simple visual stimuli, have been demonstrated to be sensitive to psychotropic agents. The present study investigated the effects of an acute dose of bromazepam (3 mg), compared with placebo, on the P100 component of the visual evoked potential and reaction time. The sample, consisting of 14 healthy subjects (6 male and 8 female), was submitted to a visual discrimination task, which employed the "oddball" paradigm. Results suggest that bromazepam (3 mg) impairs the initial stage of visual information processing, as observed by an increase in P100 latency.


Os estágios iniciais do processamento da informação visual, envolvendo a percepção e detecção de um estímulo visual simples, tem demonstrado serem sensíveis a agentes psicotrópicos. O presente estudo investigou os efeitos de uma dose aguda de bromazepam (3 mg), comparado com placebo, no componente P100 do potencial evocado visual e no tempo de reação. A mostra consistiu de 14 sujeitos sadios (6 homens e 8 mulheres), submetidos a uma tarefa de discriminação visual, a qual empregou o paradigma "oddball". Os resultados sugerem que o bromazepam (3 mg) prejudica o estágio inicial do processamento da informação visual, como observado pelo aumento da latência do P100.


Assuntos
Adulto , Feminino , Humanos , Masculino , Ansiolíticos/farmacologia , Bromazepam/farmacologia , Potenciais Evocados Visuais/efeitos dos fármacos , Análise de Variância , Eletrofisiologia , Potenciais Evocados Visuais/fisiologia , Placebos , Tempo de Reação/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...